ArticleOncotarget2017

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.

Shun Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.